Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse-033: sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab maintenance after first-line induction for pMMR endometrial cancer
MOH_2025-03-27_013995Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan and pembrolizumab in endometrial cancer (EC) (5 arms), sponsored by Merck & Co. Started Mar 2025; status: recruiting.
02
Drugs
sacituzumab govitecanpembrolizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on MOH_2025-03-27_013995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-27_013995.